Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 4/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953928 | 0.91 | GSK3B (0.55) | GSK3BCHEK1CDK2NAMPTTSHR | |
| SCHEMBL13289011 | 0.89 | GSK3B (0.56) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13289097 | 0.89 | GSK3B (0.59) | GSK3BCHEK1CDK2CCNE1NAMPT | |
| SCHEMBL13289101 | 0.88 | GSK3B (0.56) | GSK3BCHEK1CDK2CCNE1NAMPT | |
| SCHEMBL12954475 | 0.88 | GSK3B (0.58) | GSK3BCHEK1NAMPTTSHRLMNA | |
| SCHEMBL13289405 | 0.87 | GSK3B (0.57) | GSK3BCHEK1CDK2CCNE1NAMPT | |
| SCHEMBL13288938 | 0.87 | GSK3B (0.55) | GSK3BCHEK1CDK2CCNE1NAMPT | |
| SCHEMBL13120555 | 0.86 | GSK3B (0.71) | GSK3BCDK2CCNE1 | |
| SCHEMBL13289104 | 0.86 | GSK3B (0.56) | GSK3BCHEK1CDK2CCNE1NAMPT | |
| SCHEMBL14545841 | 0.86 | GSK3B (0.56) | GSK3BCHEK1NAMPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |